Direct comparisons made between the XTH43-OE and XTH43-RNAi. by Prakash M. Niraula (6816713)

Table_1_Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor... by Jan Kehr (8292456)

Table_2_Beginning of the Pandemic: COVID-19-Elicited Anxiety as a Predictor of Working Memory Performance.docx by Daniel Fellman (8583429)

“…Moreover, across three assessment points spanning 5–6 weeks, COVID-19-related anxiety levels tended to decrease over time. …”

Table_1_Beginning of the Pandemic: COVID-19-Elicited Anxiety as a Predictor of Working Memory Performance.DOCX by Daniel Fellman (8583429)

“…Moreover, across three assessment points spanning 5–6 weeks, COVID-19-related anxiety levels tended to decrease over time. …”

Supplementary Material for: Surfactant Treatment of Late Preterm Infants during Emergency Transport: A Retrospective, Observational Study by Cavallin F. (11448277)

“…<b><i>Results:</i></b> Surfactant was administered to 155/303 neonates (51.1%) at 3 different time points: at a referring hospital (50 neonates), when the transport team arrived (25 neonates), or at a referral hospital (80 neonates). …”

Dephosphorylation of AMPK substrate i.e. acetyl CoA carboxylase (ACC) initiates neuritogenic effect of SIM. by Varshiesh Raina (457377)

“…SIM led to a significant (<i>p</i> < 0.05^*) increase in pACC (Ser-79) levels at 2 hrs which was followed by a gradual decrease. …”

Modeling of the BXA-rPA_N binding interface of A(H1N1)pdm09 with E23G/K. by Jeremy C. Jones (9248188)

Molecular and functional analysis of the <i>ynfB-speG</i> operon in EIEC. by Rosaria Campilongo (626526)

Relationship between the maximum endosperm cells and the final grain dry mass (A) and endosperm dry mass (B). by Christine Girousse (5447276)

Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma by Marzena Mazur (4761027)

“…Rational design, guided by X-ray analysis of several inhibitors bound to human chitotriosidase (hCHIT1), led to the identification of compound <b>7f</b> as a highly potent AMCase inhibitor (IC₅₀ values of 14 and 19 nM against human and mouse enzyme, respectively) and selective (>150× against mCHIT1) with very good PK properties. …”

Lipid Droplet-Binding Protein TIP47 Regulates Hepatitis C Virus RNA Replication through Interaction with the Viral NS5A Protein by Dorothee A. Vogt (247917)

“…A single point mutation (W9A) in NS5A that disrupts the interaction with TIP47 but preserves proper subcellular localization severely decreased HCV RNA replication. …”

PNNs (<i>WFA</i>) were removed by ChABC microinjection into mPFC. by Wen Chen (30046)

NBQX increased PNNs (<i>WFA</i>), tenascin-R, aggrecan and Neurocan in the medial prefrontal cortex in PTZ-treated rats. by Wen Chen (30046)

Chronic PTZ treatment reduced PNNs (<i>WFA</i>), tenascin-R, aggrecan and Neurocan in the medial prefrontal cortex. by Wen Chen (30046)

mRNA levels of CASP family markers (A-E), BCL2 family markers (F-H) and other apoptosis-related markers (I-M) in limbal stromal cells (LSCs) and in Aniridia-LSCs (AN-LSCs), after t... by Shanhe Liu (5251313)

(A) Schematic presentation of the human AID protein sequence along with the positions of the lysine residues mutated in the various constructs by Said Aoufouchi (49316)

“…(D) Stable BL2 clones expressing the indicated AID-EGFP lysine mutants, WT-AID-EGFP, or mutNLS-AID-EGFP were incubated with cycloheximide (CHX, 50 μg/ml) and LMB (10 ng/ml). The decay of the protein was followed by the decrease in fluorescence intensity. …”

Effect of extended-release buprenorphine (1 mg/kg SC) on tactile hypersensitivity in a rat model of inflammation. by Christina M. Larson (18196213)

Rates of IR and ER opioid analgesic endorsement, RADARS Survey of Key Informants’ Patients Program. by Janetta L. Iwanicki (3390572)

Rates of IR and ER opioid analgesic endorsement, RADARS Opioid Treatment Program. by Janetta L. Iwanicki (3390572)

Rates of IR and ER opioid analgesic diversion, RADARS Drug Diversion Program. by Janetta L. Iwanicki (3390572)